While the role of radiation therapy in carcinoma cervix management is undauntable for all stages. Recurrent carcinoma cervix need a lot of personalisation
It describes the prevalence of Breast Cancer among BRCA 1/2 mutations with special consideration to biological background, detection and screening, actions taken upon discovering mutation carriers and whether we have a different therapeutic algorithm than sporadic cases. Special emphasis on the role of PARP inhibitors in the management of metastatic disease.
While the role of radiation therapy in carcinoma cervix management is undauntable for all stages. Recurrent carcinoma cervix need a lot of personalisation
It describes the prevalence of Breast Cancer among BRCA 1/2 mutations with special consideration to biological background, detection and screening, actions taken upon discovering mutation carriers and whether we have a different therapeutic algorithm than sporadic cases. Special emphasis on the role of PARP inhibitors in the management of metastatic disease.
Watch the slideshow: https://youtu.be/TP7iP1HEVps
Learn key concepts:
Hallmarks of cancer, Angiogenic switch, Tumor Angiogenesis
VEGF family i.e ligand and receptors, Effect of VEGF
VEGF Inhibitors or angiogenic
Bevacizumab, Ramucirumab, Ziv-Aflibercept
Audio and slides for this presentation are available on YouTube: http://youtu.be/ozNSEND5PbE
Erica Mayer, MD, MPH, of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, discusses triple-negative breast cancer and what makes it different from other forms of breast cancer. Mayer also talks about treatment options for triple-negative breast cancer and what you need to know about clinical trials for the disease.
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
Optimizing the Management of Metastatic TNBC: Diagnostics, Treatments and Hop...bkling
The treatment for mTNBC is evolving with the identification of biomarkers and clinical trials revealing new treatment options. Join us to hear from our expert guests, Dr. Paolo Tarantino, an advanced research fellow at Dana-Farber Cancer Institute and at Harvard Medical School, and Dr. Ana Garrido-Castro, Breast Medical Oncologist at Dana-Farber Cancer Institute (DFCI) and Assistant Professor of Medicine at Harvard Medical School.They will present the important changes in genetic/ biomarker diagnostics, immunotherapy as well as emerging therapies. This presentation will also highlight racial disparities and how TNBC disproportionately affects the Black community. Register now and discover your clinical options. Feel free to bring any questions you may have for discussion after the presentation.
Chair & Presenter, David R. Jones, MD, and Nathan A. Pennell, MD, PhD, FASCO, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3mFfjji. CME/MOC credit will be available until December 2, 2022.
Watch the slideshow: https://youtu.be/TP7iP1HEVps
Learn key concepts:
Hallmarks of cancer, Angiogenic switch, Tumor Angiogenesis
VEGF family i.e ligand and receptors, Effect of VEGF
VEGF Inhibitors or angiogenic
Bevacizumab, Ramucirumab, Ziv-Aflibercept
Audio and slides for this presentation are available on YouTube: http://youtu.be/ozNSEND5PbE
Erica Mayer, MD, MPH, of the Susan F. Smith Center for Women's Cancers at Dana-Farber Cancer Institute, discusses triple-negative breast cancer and what makes it different from other forms of breast cancer. Mayer also talks about treatment options for triple-negative breast cancer and what you need to know about clinical trials for the disease.
Report Back from San Antonio Breast Cancer Symposium (SABCS 2022)bkling
Curious about the latest developments in Early-Stage Breast Cancer and Metastatic Breast Cancer Research? Join us as Dr. Anne Blaes, the Division Director of Hematology/Oncology/Transplantation and Professor in Hematology/Oncology at the University of Minnesota, breaks down the most recent developments released at the annual San Antonio Breast Cancer Symposium regarding early-stage and metastatic breast cancer research.
Optimizing the Management of Metastatic TNBC: Diagnostics, Treatments and Hop...bkling
The treatment for mTNBC is evolving with the identification of biomarkers and clinical trials revealing new treatment options. Join us to hear from our expert guests, Dr. Paolo Tarantino, an advanced research fellow at Dana-Farber Cancer Institute and at Harvard Medical School, and Dr. Ana Garrido-Castro, Breast Medical Oncologist at Dana-Farber Cancer Institute (DFCI) and Assistant Professor of Medicine at Harvard Medical School.They will present the important changes in genetic/ biomarker diagnostics, immunotherapy as well as emerging therapies. This presentation will also highlight racial disparities and how TNBC disproportionately affects the Black community. Register now and discover your clinical options. Feel free to bring any questions you may have for discussion after the presentation.
Chair & Presenter, David R. Jones, MD, and Nathan A. Pennell, MD, PhD, FASCO, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “Adjuvant EGFR-Targeted Therapy as a Game Changer: How to Implement New Standards of Care in Multimodal Management of Stage I-III EGFR-Mutated NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3mFfjji. CME/MOC credit will be available until December 2, 2022.
Welcome to the dynamic world of ISOMAT. In ISOMAT we pursue perfection. For the last 30 years we have been dedicated to the evolution of constructions, therefore
we don't just produce products, but rather we develop contemporary quality solutions
for the construction sector.
Site Optimizations to Schedule Before The Holiday Code FreezeSearchSpring
With less than 80 days to Black Friday, we've partnered with Inflow to share the high value site optimizations you can make before your freeze. If you're opting to not freeze we also have optimizations you can make through holiday to drive results.
Estudio comparativo: Fogging y Refracción Cicloplegica en niñosCLINICA REMENTERIA
Clinica Rementeria | http://www.cirugiaocular.com
Estudio comparativo entre los resultados obtenidos entre Fogging y Refracción cicloplégica en niños de entre 3 y 13 años presentado en el congreso de OPTOM 2012 por el equipo de optometristas de la Clínica Rementería
El Edificio Abelias, sede tecnológica de Banco Popular, obtiene la certificac...Banco Popular
Según informó Ángel Ron, El Edificio Abelias, sede tecnológica de Banco Popular situada en Madrid, ha obtenido la certificación LEED Oro del Consejo Norteamericano de Construcción Verde (U.S. Green Building Council), la más extendida y reputada acreditación en edificación sostenible.
Para la construcción de Abelias, Banco Popular ha tenido en cuenta los estándares medioambientales más exigentes de la edificación sostenible. Asimismo ha causado el menor impacto en el entorno gracias al ahorro energético y a la reducción en el consumo de agua, poniendo de manifiesto, una vez más, el compromiso adquirido en su ‘Declaración de Política Medioambiental’.
12. 10- and 15-year OSRafor Connecticut and San Francisco-Oakland registry for 1981–1985 and 1991–1995 cohorts with 95% confidence intervals in brackets (SEER data) Tai P, BMC Cancer 2004;4:60 N.A. 2.4 (1.2-3.6) 15 yıl 8.8 (5.7-11.9) 4.6 (2.8-6.4) 10 yıl San Fransisco-Oakland N.A. 3.2 (2.0-4.4) 15 yıl 7.2 (3.7-10.7) 6.4 (4.6-8.2) 10 yıl Connecticut 1991-1995 OSR (%) 1981-1985 OSR (%)
13.
14. Primer Tm ile Metastatik ve Lokal Rekürrens Arasında Diskordans Idirisinghe PK, Am J Clin Pathol 133:416-29,2010 % 2 % 7 erbB2 P=.017 % 33 % 42 PR % 13 % 18 ER Met veya lokal nüks Primer Tm
15. Broom RJ, Anticancer Res 29:1557, 2009 Primer Tm ile Metastatik ve Lokal Rekürrens Arasında Diskordans % 37.3 PR % 8 ER- -> ER+ % 9.7 ER+ -> ER- % 17.7 ER Diskordans Reseptör
16.
17.
18.
19.
20.
21.
22.
23. A: HR negatif grup B: HR pozitif grup Dawood S, JCO 28;20-28:2010
24.
25.
26.
27.
28.
29.
30.
31.
32. Lower EE , Breast Cancer Res Treat 113:301-6,2009 erbB2 Durumuna Göre Hastalar % 14.1 % 9.2 % 25 %51.6 PR % 16.1 % 9.1 % 36 % 49.7 ER +/+ -/+ +/- -/- % 35.7 - Prediktif - - 205 % 84.6 + Prediktif + + 50 % 60.4 Spes + - 37 % 57.5 Sens - + 90 Metastatik Tm Primer tm erbB N
33. Lower EE , Breast Cancer Res Treat 113:301-6,2009 Fig. 1 Kaplan Meier curves showing probability of survival from the time of original diagnosis versus four groups based on HER/2 neu status in primary and metastatic lesion: Group 1 (negative/negative); Group 2 (positive/negative); Group 3 (negative/positive); Group 4 (positive/positive). This difference between the groups was significant (χ2 = 13.03, P < 0.005)
34. Fig. 2 Kaplan Meier curves showing probability of survival from the time of first diagnosis of metastases versus four groups based on HER/2 neu status in primary and metastatic lesion: Group 1 (negative/negative); Group 2 (positive/negative); Group 3 (negative/positive); Group 4 (positive/positive). There was no significant difference between groups (χ2 = 5.76, P > 0.05) Lower EE , Breast Cancer Res Treat 113:301-6,2009